Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology

Business News
Print
GUANGZHOU, China & SAN DIEGO--(BUSINESS WIRE)--Burning Rock and Illumina, Inc. (NASDAQ: ILMN) today announced they have entered into an agreement whereby Burning Rock will develop advanced clinical applications for molecular diagnostics in oncology based on Illumina’s next-generation sequencing (NGS) technology. The collaboration highlights the ever-increasing importance of genomics to improve healthcare in China. In recent years, NGS has evolved rapidly and is widely regarded as an essential t

imageimage
image

Read more